PDCD1 and non-small cell lung carcinoma: A case of advanced driver gene-negative NSCLC achieved imaging-confirmed complete response following anti-PD-L1 antibody (atezolizumab) therapy after progression on anti-PD-1 (nivolumab) treatment (38).